Dual Action of Dipyridamole in Experimental Rheumatoid Arthritis: Suppression of Joint Inflammation and Upregulation of Muscle Anabolism via Adenosine and AMPK Pathways - Takeaways - MDSpire

Biphasic Effects of Dipyridamole in Experimental Models of Rheumatoid Arthritis: Inhibition of Joint Inflammation and Enhancement of Muscle Anabolism through Adenosine and AMPK Signaling Pathways

  • By

  • Miguel Marco-Bonilla

  • Maria Fresnadillo

  • Irene Sanchez-Platero

  • Macarena de la Riva-Bueno

  • Fernando Huete-Toral

  • Gonzalo Carracedo

  • Carmen Conde

  • Yolanda Benitez

  • Pablo Minguez

  • Sandra Carolina Cifuentes

  • Joaquin Rams

  • Gabriel Herrero-Beaumont

  • Raquel Largo

  • Aránzazu Mediero

  • July 1, 2026

Share

  • 1

    Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to joint inflammation and can cause muscle atrophy and changes in body composition.

  • 2

    Muscle loss in RA, termed rheumatoid sarcopenia, affects 20% to 44% of patients and is linked to increased inflammation and elevated catabolic processes.

  • 3

    Methotrexate and biologic DMARDs are ineffective in improving muscle condition in RA, indicating a need for alternative therapeutic strategies.

  • 4

    Dipyridamole increases extracellular adenosine levels, activating A2AR and A2BR, which may provide anti-inflammatory effects and support muscle health.

  • 5

    The study aims to explore the therapeutic potential of dipyridamole in RA and its role in modulating muscle pathology through purinergic signaling.

Original Source(s)

Dual Action of Dipyridamole in Experimental Rheumatoid Arthritis: Suppression of Joint Inflammation and Upregulation of Muscle Anabolism via Adenosine and AMPK Pathways

  • by Miguel Marco-Bonilla, Maria Fresnadillo, Irene Sanchez-Platero, Macarena de la Riva-Bueno, Fernando Huete-Toral, Gonzalo Carracedo, Carmen Conde, Yolanda Benitez, Pablo Minguez, Sandra Carolina Cifuentes, Joaquin Rams, Gabriel Herrero-Beaumont, Raquel Largo, Aránzazu Mediero

  • July 1, 2026

Related Content

IL-34-mediated fibroblast-like synoviocyte-macrophage crosstalk drives bone erosion in rheumatoid arthritis through RANKL-dependent osteoclastogenesis

Depressive symptoms and risk of incident activities of daily living disability among older adults with symptomatic arthritis

Maresin-1 and maresin-2 as synovial fluid biomarkers in psoriatic, rheumatoid, and osteoarthritis